Affluent Medical : Successful first post-operative adjustment of KaliosTM mitral ring.

Affluent Medical
Affluent Medical : Successful first post-operative adjustment of KaliosTM mitral ring.

16-Sep-2021 / 17:45 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Aix-en-Provence, 16 September 2021 - 5.45 p.m.




Successful first post-operative adjustment

of KaliosTM mitral ring



Affluent Medical (ISIN: FR0013333077 - ticker: AFME), a French medtech specialising in the international development and industrial scale-up of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and cardiac mitral insufficiency, today announces the success of the first ever KaliosTM mitral ring adjustment on a patient suffering from post-operative recurrence of severe mitral insufficiency.


Prof. Alberto Albertini (GMV Maria Cecilia Hospital de Cotignola, Italy) successfully performed the percutaneous adjustment of the original KaliosTM annuloplasty ring 11 months after its implantation following a recurrence of severe mitral insufficiency.


Following successful implantation of a KaliosTM adjustable mitral ring, a simple trace of residual leakage was observed in a patient, who was operated in August 2020 for major mitral insufficiency (4+)[1],following a myocardial infarction.


Following a period of stability, a major mitral incompetence (regurgitation) of grade 4+ and NYHA IV occurred as a result of deterioration and dilation of the left ventricle requiring further intervention in order to absorb the leak and improve the patient's prognosis.


The adjustment was carried out in July 2021 without surgery by inserting balloons into the subcutaneous line in order to reduce the size of the ring under ultrasound control, thereby substantially reducing the leak to its initial level (1+) and allowing the immediate result to be verified.


The patient, who is under programmed medical monitoring, is currently classified NYHA I[2] and is therefore not limited with regard to everyday activities.


Prof. Alberto Albertini confirmed: "The KaliosTM device allowed a simple and efficient intervention via the transcatheter route, offering the patient a solution that avoided further, more complex open-heart surgery involving a longer hospital stay, along with all the associated risks." 


Affluent Medical's Chief Medical Officer Prof. François Laborde confirmed that the KaliosTM device was a major breakthrough in treating mitral regurgitation and its recurrence, which happens between 30% and 40% of the redo mitral incompetence as reported in the medical literature. This also underlines the innovative nature of the KaliosTM device, which combines an established surgical technique with a potential future transcatheter adjustment depending on how mitral regurgitation develops in the patient.

"KaliosTM is a unique future solution unrivalled on the current market for both the patient and the healthcare system, in that it is expected to offer major medico-economic benefits that should help understand mitral regurgitation better and improve its treatment in the future." 






About KaliosTM

KaliosTM is the only ring designed for mitral valve repair optimised for minimally invasive cardiac surgery and allowing multiple post-operative readjustments via the transcatheter route - without invasive reoperation. It is therefore a unique hybrid technology.

A pivotal study is currently underway in Austria, Germany, Switzerland and Italy and a number of patients have already been recruited.



About Affluent Medical

Affluent Medical is a French medtech company founded by Truffle Capital with the aim of becoming a global leader in the treatment of cardiovascular diseases, which are the leading cause of death worldwide, and of urinary incontinence, which today affects one in four adults. Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas. The four main technologies developed by the company are currently at the stage of preclinical and clinical studies. The first medical device is expected to go to market by 2023 with KaliosTM in Europe.

Read more: www.affluentmedical.com




[1] (4+): A level corresponding to the condition of a patient unable to perform ordinary daily tasks without discomfort, including at rest.

[2] NYHA: The NYHA classification is a scale of diagnostic, prognostic and therapeutic interest that expresses the clinical severity of heart failure.

Regulatory filing PDF file

File: Affluent Medical - Kalios EN

Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / Other releases
EQS News ID: 1234061
End of Announcement EQS News Service

1234061  16-Sep-2021 CET/CEST

Source: EQS Newswire

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr


Redan prenumerant?